Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
5-MeO-DMT · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 5-MeO-DMT arm | EXPERIMENTAL | - |
| Placebo arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 5-MeO-DMT | DRUG | A single dose of 5-MeO-DMT will be administered intranasally |
| Placebo | OTHER | A single dose of placebo will be administered intranasally |
Inclusion Criteria: \* Medically healthy based on medical records and study specific assessments Exclusion Criteria: \* Presence or history of severe adverse reaction to any drug or drug excipient
5-MeO-DMT is an investigational small molecule being studied for pharmacokinetics in healthy adults. It is currently in Phase 1 clinical development, with a completed single ascending dose study in healthy volunteers. The drug is not approved and remains under investigation.
5-MeO-DMT is being developed by AtaiBeckley Inc., a biopharmaceutical company. The company's stock is traded under the ticker ATAI. The drug is currently in Phase 1 clinical development for pharmacokinetics in healthy adults.
5-MeO-DMT is in Phase 1 clinical development. A single ascending dose study in healthy subjects has been completed. The drug is investigational and has not been approved for any use.
5-MeO-DMT has one completed Phase 1 trial, NCT05032833, titled 'Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects.' This randomized, double-blind, placebo-controlled study enrolled 36 healthy adults in the United Kingdom.
5-MeO-DMT is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed trial, NCT05032833, studied its pharmacokinetics in healthy adults, but the drug remains under investigation.